William Kaelin

William G.
Kaelin is the founder of Tango Therapeutics Sub, Inc. (founded in 2017), Cedilla Therapeutics, Inc. (founded in 2017), and Tango Therapeutics, Inc. (founded in 2017).
Current jobs include Independent Director at Eli Lilly & Co. since 2012, Director at The Damon Runyon Cancer Research Foundation, Director at LifeMine Therapeutics, Inc. since 2021, Director at IconOVir Bio, Inc. since 2022, Independent Director at IQVIA Holdings, Inc. starting 2025, Trustee at Duke University, Professor at Dana-Farber Cancer Institute, Inc., Professor at The Brigham & Women's Hospital, Inc. since 2002, Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the Association of American Physicians, Member of Dana-Farber, Member of the American Society of Clinical Investigation, Professor at Harvard Medical School since 2002, and Advisor at Casdin Capital.
Former jobs include Chief Resident & House Officer at The Johns Hopkins Hospital, Inc., Member-Advisory Board at National Cancer Institute, Member of the National Academy of Medicine (United States), Member of the American College of Physicians, Inc., and Trustee of the American Association for Cancer Research.
Education includes an undergraduate degree from Duke University conferred in 1982 and a doctorate from Duke University School of Medicine.